Lead Product(s) : Vodobatinib
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PROSEEK Study Shows No Treatment Benefit of Vodobatinib in Early Parkinson's Disease
Details : K0706 (vodobatinib) is a c-Abl kinase inhibitor, oral capsule small molecule drug candidate, which is currently being evaluated for the treatment of patients with parkinson’s disease.
Product Name : K0706
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 04, 2024
Lead Product(s) : Vodobatinib
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vodobatinib
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SPARC Completes Enrolment in PROSEEK, Phase 2 Study of Vodobatinib in Early Parkinson’s Disease
Details : K0706 (vodobatinib) is a potential first-in-class, highly selective and brain penetrating c-Abl inhibitor. It is being evaluated in patients with Parkinson’s disease, Dementia with Lewy Body and Chronic Myelogenous Leukemia.
Product Name : K0706
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 30, 2023
Lead Product(s) : Vodobatinib
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
